The Center for the Development of Therapeutics (CDoT) enables many aspects of the drug discovery process to help biological insights become new therapeutics.
Scientists have solved the structure of an important complex of RAS-pathway proteins, explaining how known mutations lead to disease and suggesting potential new binding sites for cancer drugs.
Researchers find that several genetic disorders, including MUC1 kidney disease, may share a novel molecular mechanism — and identify a promising therapeutic lead.